Drug research

Atezolizumab

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as Tecentriq; Tecentriq (Brand name); Tecentriq®

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer TherapyNCT03755791	Exelixis	Phase 3	Active not recruiting	2021-11-30Actual
Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal CancerNCT05425940	Exelixis	Phase 3	Active not recruiting	2026-06-16Actual
EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal AdenocarcinomaNCT06390059	NVCR	Phase 2	Completed	2025-11-18Actual
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCCNCT05733598	Replimune, Inc.	Phase 2	Recruiting	2027-12-01Estimated
A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic TherapyNCT06680258	Tempest Therapeutics	Phase 3	Not yet recruiting	2028-12Estimated
Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored StudyNCT07620574	Exelixis	Phase 3	Enrolling by invitation	2030-05-31Estimated
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPCNCT04446117	Exelixis	Phase 3	Active not recruiting	2024-04-19Actual
Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular CarcinomaNCT05359861	CHRS	Phase 2	Completed	2025-06-30Actual

Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy

ExelixisActive not recruitingPrimary completion: 2021-11-30 · Actual

Trial details

Registry ID: NCT03755791
Phase: Phase 3

Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer

ExelixisActive not recruitingPrimary completion: 2026-06-16 · Actual

Trial details

Registry ID: NCT05425940
Phase: Phase 3

EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma

NVCRCompletedPrimary completion: 2025-11-18 · Actual

Trial details

Registry ID: NCT06390059
Phase: Phase 2

Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

Replimune, Inc.RecruitingPrimary completion: 2027-12-01 · Estimated

Trial details

Registry ID: NCT05733598
Phase: Phase 2

A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy

Tempest TherapeuticsNot yet recruitingPrimary completion: 2028-12 · Estimated

Trial details

Registry ID: NCT06680258
Phase: Phase 3

Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study

ExelixisEnrolling by invitationPrimary completion: 2030-05-31 · Estimated

Trial details

Registry ID: NCT07620574
Phase: Phase 3

Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC

ExelixisActive not recruitingPrimary completion: 2024-04-19 · Actual

Trial details

Registry ID: NCT04446117
Phase: Phase 3

Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma

CHRSCompletedPrimary completion: 2025-06-30 · Actual

Trial details

Registry ID: NCT05359861
Phase: Phase 2

Regulatory dates and decisions

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.